During his visit to Australia last week for Orthocell’s annual nerve repair and reconstruction symposium, US reconstructive surgeon Dr Ian Valerio made the time to speak with Stockhead’s Tylah Tully about the significant global opportunity for Remplir, following recent FDA approval.
He noted that the technology’s proven track record in Australia positions it well for expansion into other markets, with potential to establish Orthocell as a market leader in nerve repair and regenerative surgery globally.